Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2
暂无分享,去创建一个
V. Arlt | E. Frei | M. Stiborová | J. Poljaková | M. Moserová | V. Kotrbová | D. Aimová
[1] V. Arlt,et al. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. , 2008, Toxicology and applied pharmacology.
[2] V. Arlt,et al. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo : experiments with Hepatic Cytochrome P450 Reductase Null mice , 2008 .
[3] R. Vaclavikova,et al. The Anticancer Drug Ellipticine Is a Potent Inducer of Rat Cytochromes P450 1A1 and 1A2, Thereby Modulating Its Own Metabolism , 2007, Drug Metabolism and Disposition.
[4] E. Frei,et al. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. , 2007, Cancer letters.
[5] E. Frei,et al. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. , 2007, Toxicology.
[6] E. Frei,et al. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12‐hydroxyellipticine and 13‐hydroxyellipticine , 2007, International journal of cancer.
[7] E. Frei,et al. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. , 2006, Neuro endocrinology letters.
[8] J. Hudeček,et al. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. , 2006, General physiology and biophysics.
[9] Eva Frei,et al. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. , 2006, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[10] D. Nebert,et al. Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate , 2006, Molecular Pharmacology.
[11] V. Arlt,et al. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. , 2006, Cancer letters.
[12] C. Wolf,et al. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. , 2006, Toxicology letters.
[13] J. Hudeček,et al. The Effect of pH on Peroxidase-Mediated Oxidation of and DNA Adduct Formation by Ellipticine , 2006 .
[14] Václav Martínek,et al. Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. , 2005, Cancer letters.
[15] B. Sopko,et al. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. , 2005, Cancer research.
[16] B. Mahadevan,et al. Carcinogenic polycyclic aromatic hydrocarbon‐DNA adducts and mechanism of action , 2005, Environmental and molecular mutagenesis.
[17] J. Hudeček,et al. The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide , 2004, Cancer Research.
[18] V. Arlt,et al. 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2. , 2004, Chemical research in toxicology.
[19] D. Nebert,et al. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.
[20] E. Frei,et al. DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells , 2004 .
[21] E. Frei,et al. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling , 2003, International journal of cancer.
[22] V. Arlt,et al. Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome p450 reductase. , 2003, Cancer research.
[23] C. Wolf,et al. Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.
[24] E. Frei,et al. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. , 2003, Chemical research in toxicology.
[25] D. Phillips. Smoking-related DNA and protein adducts in human tissues. , 2002, Carcinogenesis.
[26] V. Arlt,et al. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. , 2002, Biochemical pharmacology.
[27] E. Frei,et al. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.
[28] D. Phillips,et al. Polycyclic aromatic hydrocarbons in the diet. , 1999, Mutation research.
[29] R. E. Kouri,et al. Relationships between aryl hydrocarbon hydroxylase inducibility and sensitivity to chemically induced subcutaneous sarcomas in various strains of mice. , 1973, Journal of the National Cancer Institute.